Capital Fund Management S.A. Has $821,000 Stock Holdings in LivaNova PLC (NASDAQ:LIVN)

Capital Fund Management S.A. cut its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 31.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,718 shares of the company's stock after selling 7,992 shares during the quarter. Capital Fund Management S.A.'s holdings in LivaNova were worth $821,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of LIVN. Nordea Investment Management AB lifted its stake in LivaNova by 22.2% during the fourth quarter. Nordea Investment Management AB now owns 68,711 shares of the company's stock valued at $3,188,000 after buying an additional 12,470 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new position in LivaNova during the 4th quarter worth approximately $1,954,000. KBC Group NV raised its stake in LivaNova by 130.5% during the 4th quarter. KBC Group NV now owns 99,928 shares of the company's stock valued at $4,628,000 after purchasing an additional 56,580 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of LivaNova by 29.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock worth $292,000 after buying an additional 1,424 shares during the period. Finally, Rhumbline Advisers grew its holdings in shares of LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock valued at $8,240,000 after buying an additional 899 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Trading Up 1.5 %

LivaNova stock traded up $0.51 during midday trading on Friday, hitting $35.58. 614,570 shares of the stock were exchanged, compared to its average volume of 627,934. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $64.48. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $1.93 billion, a PE ratio of 84.71 and a beta of 0.90. The company has a fifty day simple moving average of $40.08 and a two-hundred day simple moving average of $46.71.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on LIVN shares. The Goldman Sachs Group decreased their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Needham & Company LLC reiterated a "buy" rating and issued a $64.00 target price on shares of LivaNova in a research report on Monday, March 17th. StockNews.com upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a report on Tuesday, March 25th. Mizuho decreased their target price on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. Finally, Barclays cut their price target on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating on the stock in a report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, LivaNova presently has an average rating of "Buy" and an average target price of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.